Monsanto Co. (NYSE:MON) released its earnings results on Wednesday. The company reported $0.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.09. Monsanto had a return on equity of 37.98% and a net margin of 7.76%. The company had revenue of $2.56 billion for the quarter, compared to analysts’ expectations of $2.38 billion. During the same quarter in the previous year, the business posted ($0.19) EPS. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. Monsanto updated its FY17 guidance to $4.50-4.90 EPS.
Shares of Monsanto (NYSE:MON) opened at 103.50 on Friday. The company has a market capitalization of $45.29 billion, a PE ratio of 45.55 and a beta of 1.19. Monsanto has a 12 month low of $83.73 and a 12 month high of $114.26. The firm has a 50-day moving average price of $104.88 and a 200-day moving average price of $101.34.
The business also recently declared a quarterly dividend, which will be paid on Friday, October 28th. Shareholders of record on Friday, October 7th will be given a $0.54 dividend. This represents a $2.16 dividend on an annualized basis and a yield of 2.09%. The ex-dividend date of this dividend is Wednesday, October 5th. Monsanto’s dividend payout ratio (DPR) is 89.26%.
In other Monsanto news, COO Brett D. Begemann sold 27,980 shares of the company’s stock in a transaction dated Thursday, July 14th. The stock was sold at an average price of $103.62, for a total value of $2,899,287.60. Following the sale, the chief operating officer now owns 102,480 shares in the company, valued at approximately $10,618,977.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael K. Stern sold 12,797 shares of the company’s stock in a transaction dated Wednesday, July 13th. The shares were sold at an average price of $101.77, for a total value of $1,302,350.69. Following the completion of the sale, the chief executive officer now owns 21,583 shares in the company, valued at approximately $2,196,501.91. The disclosure for this sale can be found here. Corporate insiders own 0.88% of the company’s stock.
Several large investors have recently added to or reduced their stakes in MON. Mycio Wealth Partners LLC raised its stake in Monsanto by 1.1% in the second quarter. Mycio Wealth Partners LLC now owns 1,094 shares of the company’s stock worth $113,000 after buying an additional 12 shares during the period. Moody National Bank Trust Division raised its stake in Monsanto by 0.3% in the second quarter. Moody National Bank Trust Division now owns 4,883 shares of the company’s stock worth $505,000 after buying an additional 15 shares during the period. Quadrant Capital Group LLC raised its stake in Monsanto by 0.9% in the second quarter. Quadrant Capital Group LLC now owns 1,858 shares of the company’s stock worth $184,000 after buying an additional 16 shares during the period. Advisor Partners LLC raised its stake in Monsanto by 0.4% in the second quarter. Advisor Partners LLC now owns 6,238 shares of the company’s stock worth $645,000 after buying an additional 23 shares during the period. Finally, Trust Co. of Vermont raised its stake in Monsanto by 0.6% in the second quarter. Trust Co. of Vermont now owns 4,932 shares of the company’s stock worth $510,000 after buying an additional 30 shares during the period. Hedge funds and other institutional investors own 79.02% of the company’s stock.
MON has been the topic of several research analyst reports. S&P Equity Research reaffirmed a “positive” rating on shares of Monsanto in a research note on Thursday, September 15th. Vetr raised Monsanto from a “buy” rating to a “strong-buy” rating and set a $116.55 target price on the stock in a research note on Monday, June 27th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $118.00 target price on shares of Monsanto in a research note on Sunday, August 21st. Citigroup Inc. reaffirmed a “neutral” rating and set a $112.00 target price on shares of Monsanto in a research note on Monday, July 18th. Finally, Goldman Sachs Group Inc. set a $92.00 target price on Monsanto and gave the company a “sell” rating in a research note on Monday, June 27th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Monsanto has a consensus rating of “Buy” and an average target price of $114.67.
Monsanto Company Profile
Monsanto Company (Monsanto), along with its subsidiaries, is a provider of agricultural products for farmers. The Company provides seeds, biotechnology trait products, herbicides and precision agriculture tools to farmers. The Company operates through two segments: Seeds and Genomics, and Agricultural Productivity.
Receive News & Ratings for Monsanto Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monsanto Co. and related companies with MarketBeat.com's FREE daily email newsletter.